Brought to you by 
Series B venture round brings in $7.9mm for Clearside Biomedical, which closes financing at $16mm
11 May 2015
Executive Summary
Clearside Biomedical Inc. (ophthalmic drug delivery that does not require surgery) has raised $7.9mm through its Series B venture round. There were 13 investors, including new backer Mountain Group Capital and current shareholders Hatteras Venture Partners, Georgia Research Alliance Venture Fund, and Kenan Flagler Business School Private Equity Fund. Santen Pharmaceutical Co. Ltd. also participated as part of its concurrently announced research alliance for posterior ocular disease therapeutics.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B venture round brings in $7.9mm for Clearside Biomedical, which closes financing at $16mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice